Zelira Therapeutics Limited (ZLD.AX)
AUD 0.39
(-4.88%)
AUD 0.39
(-4.88%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 9.35 Million AUD | 329.42% |
| 2023 | 2.17 Million AUD | 8.35% |
| 2022 | 2.01 Million AUD | 30.92% |
| 2021 | 1.53 Million AUD | 23.71% |
| 2020 | 1.24 Million AUD | 204.91% |
| 2019 | 407.23 Thousand AUD | 309.6% |
| 2018 | 99.42 Thousand AUD | 40.78% |
| 2017 | 70.62 Thousand AUD | -75.68% |
| 2016 | 290.42 Thousand AUD | 476.3% |
| 2015 | 50.39 Thousand AUD | 67.95% |
| 2014 | 30 Thousand AUD | -21.29% |
| 2013 | 38.12 Thousand AUD | -51.87% |
| 2012 | 79.2 Thousand AUD | -62.98% |
| 2011 | 213.94 Thousand AUD | 426.61% |
| 2010 | 40.62 Thousand AUD | -96.2% |
| 2009 | 1.06 Million AUD | 768.71% |
| 2008 | 123.05 Thousand AUD | -99.49% |
| 2007 | 24.11 Million AUD | 108.33% |
| 2006 | 11.57 Million AUD | 7991.23% |
| 2005 | 143.06 Thousand AUD | -43.27% |
| 2004 | 252.17 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 9.35 Million AUD | 0.0% |
| 2024 Q2 | 5.21 Million AUD | 0.0% |
| 2024 FY | 9.35 Million AUD | 329.42% |
| 2023 FY | 2.17 Million AUD | 8.35% |
| 2023 Q2 | 2.62 Million AUD | 0.0% |
| 2023 Q4 | 2.17 Million AUD | 0.0% |
| 2022 Q2 | 1.35 Million AUD | 0.0% |
| 2022 Q4 | 2.01 Million AUD | 0.0% |
| 2022 FY | 2.01 Million AUD | 30.92% |
| 2021 Q2 | 1.12 Million AUD | 0.0% |
| 2021 Q4 | 1.53 Million AUD | 0.0% |
| 2021 FY | 1.53 Million AUD | 23.71% |
| 2020 Q2 | 663.35 Thousand AUD | 0.0% |
| 2020 FY | 1.24 Million AUD | 204.91% |
| 2020 Q4 | 1.24 Million AUD | 0.0% |
| 2019 FY | 407.23 Thousand AUD | 309.6% |
| 2019 Q2 | 576.85 Thousand AUD | 0.0% |
| 2019 Q4 | 407.23 Thousand AUD | 0.0% |
| 2018 Q4 | 99.42 Thousand AUD | 0.0% |
| 2018 FY | 99.42 Thousand AUD | 40.78% |
| 2018 Q2 | 88.58 Thousand AUD | 0.0% |
| 2017 FY | 70.62 Thousand AUD | -75.68% |
| 2017 Q4 | 70.62 Thousand AUD | 0.0% |
| 2017 Q2 | 576.63 Thousand AUD | 0.0% |
| 2016 Q4 | 290.42 Thousand AUD | 0.0% |
| 2016 FY | 290.42 Thousand AUD | 476.3% |
| 2016 Q2 | 260.03 Thousand AUD | 0.0% |
| 2015 Q4 | 50.39 Thousand AUD | 0.0% |
| 2015 FY | 50.39 Thousand AUD | 67.95% |
| 2014 Q4 | 30 Thousand AUD | 0.0% |
| 2014 FY | 30 Thousand AUD | -21.29% |
| 2013 Q4 | 38.12 Thousand AUD | 0.0% |
| 2013 FY | 38.12 Thousand AUD | -51.87% |
| 2012 FY | 79.2 Thousand AUD | -62.98% |
| 2012 Q4 | 79.2 Thousand AUD | 0.0% |
| 2011 Q4 | 213.94 Thousand AUD | 0.0% |
| 2011 FY | 213.94 Thousand AUD | 426.61% |
| 2010 Q4 | 40.62 Thousand AUD | 0.0% |
| 2010 FY | 40.62 Thousand AUD | -96.2% |
| 2009 Q4 | 1.06 Million AUD | 0.0% |
| 2009 FY | 1.06 Million AUD | 768.71% |
| 2008 FY | 123.05 Thousand AUD | -99.49% |
| 2008 Q4 | 123.05 Thousand AUD | 0.0% |
| 2007 FY | 24.11 Million AUD | 108.33% |
| 2007 Q4 | 24.11 Million AUD | 0.0% |
| 2006 FY | 11.57 Million AUD | 7991.23% |
| 2006 Q4 | 11.57 Million AUD | 0.0% |
| 2005 FY | 143.06 Thousand AUD | -43.27% |
| 2005 Q4 | 143.06 Thousand AUD | 0.0% |
| 2004 FY | 252.17 Thousand AUD | 0.0% |
| 2004 Q4 | 252.17 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | -164.12% |
| Acrux Limited | 5.68 Million AUD | -64.526% |
| Race Oncology Limited | 1.91 Million AUD | -388.231% |
| Biome Australia Limited | 5.37 Million AUD | -74.132% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -150.707% |
| BTC Health Limited | 203.94 Thousand AUD | -4487.732% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 26.919% |
| CSL Limited | 27.88 Billion AUD | 99.966% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | -12.3% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 66.717% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -121.241% |
| Hexima Limited | 248.67 Thousand AUD | -3662.652% |
| Immutep Limited | 10.97 Million AUD | 14.782% |
| Memphasys Limited | 5.59 Million AUD | -67.309% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 78.12% |
| Noxopharm Limited | 1.28 Million AUD | -626.097% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -302.336% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 79.06% |
| Starpharma Holdings Limited | 8.69 Million AUD | -7.572% |
| Tissue Repair Ltd | 1.35 Million AUD | -592.617% |
| Biotron Limited | 737.5 Thousand AUD | -1168.676% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -72.45% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -2949.248% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -2439.473% |
| Patrys Limited | 691.36 Thousand AUD | -1253.35% |
| Orthocell Limited | 22.08 Million AUD | 57.629% |
| Imugene Limited | 33.14 Million AUD | 71.769% |
| PYC Therapeutics Limited | 10.18 Million AUD | 8.125% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -475.462% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -698.988% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -354.946% |
| Nanollose Limited | 465.64 Thousand AUD | -1909.391% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -2067.733% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -10820.004% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -173.042% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -794.833% |
| Nyrada Inc. | 855.63 Thousand AUD | -993.528% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 96.248% |
| Dimerix Limited | 13.89 Million AUD | 32.653% |
| PharmAust Limited | 896.6 Thousand AUD | -943.555% |
| AnteoTech Limited | 4.07 Million AUD | -129.595% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -161.041% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 41.129% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -893.754% |
| Actinogen Medical Limited | 1.61 Million AUD | -479.223% |
| Immuron Limited | 2.84 Million AUD | -229.396% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -285.565% |